Omeza
Omeza is a commercial-stage advanced wound care company developing OCM™, an FDA-cleared drug-device combination wound matrix derived from marine cold water fish peptides. The Sarasota, Florida-based company sells through an exclusive nationwide partnership with Advanced Solution, a VA Federal Supply Schedule listing via Marathon Medical, and direct HCP sales for chronic wound treatment.
- Company typePrivate
- Founded2014
- HeadquartersSarasota, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Omeza does
Omeza is a commercial-stage advanced wound care company founded in 2014 and headquartered in Sarasota, Florida. Its lead product is OCM™ (Omeza Collagen Matrix), a first-of-its-kind FDA-cleared drug-device combination wound matrix made from sustainably sourced marine-derived cold water fish peptides, marine collagen, omega-3/-6/-9 oils, and pharmaceutical-grade components. OCM™ is delivered in single-use disposable vials applied directly to the wound bed and is positioned as a multimodal therapy addressing inflammation, proliferation, remodeling, and biofilm impact in a single product — eliminating the typical 30-day waiting period for advanced wound care access. The supporting portfolio includes Omeza® Lidocaine Lavage and Omeza® Skin Protectant, historically bundled with OCM™ as a complete chronic-wound care regimen.
The company generates revenue through three channels: an exclusive national U.S. commercialization partnership with Advanced Solution covering all outpatient settings (launched May 19, 2025 with full nationwide rollout by Summer 2025), a government channel via Marathon Medical as prime vendor on the VA Federal Supply Schedule serving VA/DOD/IHS physicians, and direct commercial sales to non-government HCPs and clinics. OCM™ is reimbursed under CMS code A2014. Pricing is quote-based and not publicly disclosed.
Omeza's go-to-market is clinical-evidence-led, anchored by completed clinical trials in diabetic foot ulcers (n=19, 94% PAR at 12 weeks), venous leg ulcers (n=33), and a multi-etiology study (n=111 across DFU, VLU, pressure injuries, pyoderma gangrenosum, surgical, arterial, and unclassified wounds), five+ peer-reviewed publications in Advances in Therapy, Journal of Wound Care, Advances in Skin and Wound Care, and International Wound Journal, and active presence at major wound care conferences (SAWC, WOCNEXT, EWMA, APWCA). The company closed an $8.5 million Series A financing in April 2026 co-led by Astanor and BluKap Ventures, and operates with 11-50 employees under a leadership team including CEO Cynthia Flowers (former President and CEO of Ipsen North America), CSO Suzanne Bakewell, Ph.D., CFO Kris Smeage, and CMO Desmond Bell, DPM.
Omeza firmographics
Firmographics- Name
- Omeza
- Legal name
- Omeza Holdings, Inc.
- Website
- https://omeza.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Omeza is a commercial-stage advanced wound care company developing OCM™, an FDA-cleared drug-device combination wound matrix derived from marine cold water fish peptides. The Sarasota, Florida-based company sells through an exclusive nationwide partnership with Advanced Solution, a VA Federal Supply Schedule listing via Marathon Medical, and direct HCP sales for chronic wound treatment.
- Ownership category
- akta.pro rank
Omeza industry classification
Industry- Product category
- Advanced Wound Care
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industry
- Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)
Keywords
Where Omeza is headquartered
LocationHeadquarters
- HQ city
- Sarasota
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Omeza business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Marketing or Sales, Technology or R&D, Personnel, Supply Chain
Revenue model
- OCM™ product sales via exclusive distributor: Omeza generates revenue through sale of OCM™ wound matrix units (single-dose vials and multi-pack cartons) via Advanced Solution, which holds exclusive national commercialization rights across all outpatient settings. Nationwide commercial launch began May 19, 2025 with full rollout by Summer 2025. Reimbursed under CMS code A2014.
- Government channel sales (VA/DOD/IHS): Sales of OCM™ to U.S. Department of Veterans Affairs, Department of Defense, and Indian Health Service physicians through Marathon Medical, a prime vendor on the Veterans Affairs Federal Supply Schedule (Contract 36F79718D0321).
- Direct commercial product sales: Direct product sales to healthcare professionals and clinics for non-government commercial customers via Omeza customer service ([email protected], 888-886-6392). Single-use vial packaging: 4-pk and 10-pk cartons for commercial sale.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | OCM™ commercial pricing - quote based |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels6 records
Omeza product offering
Product offeringCore offering
Omeza develops and manufactures OCM™ (Omeza Collagen Matrix), an FDA-cleared drug-device combination wound matrix made from cold water fish peptides and pharmaceutical-grade marine compounds. The product is delivered in single-use disposable vials and administered by healthcare professionals to address all phases of chronic wound healing — inflammation, proliferation, and remodeling — for partial/full-thickness wounds, diabetic foot ulcers, venous leg ulcers, pressure ulcers, tunneled wounds, surgical wounds, and trauma wounds. The portfolio also historically includes Omeza® Lidocaine Lavage and Omeza® Skin Protectant as part of a bundled treatment regimen, distributed nationally via an exclusive partnership with Advanced Solution and through the VA Federal Supply Schedule via Marathon Medical.
Product overview
Omeza is a commercial-stage advanced wound-care company built around a single core platform product, OCM™ (Omeza Collagen Matrix), an FDA-cleared drug-device combination wound matrix derived from cold water fish peptides and other pharmaceutical-grade components. OCM™ is the lead product and primary commercial offering, applied directly to the wound bed by healthcare professionals to address all phases of wound healing (decrease inflammation, increase proliferation, support remodeling, reduce biofilm impact). The portfolio also includes two supporting sub-products that have historically been bundled with OCM™ as the 'Omeza products bundle': Omeza® Lidocaine Lavage and Omeza® Skin Protectant, which together form a multi-modal wound-care treatment line for chronic wounds including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other non-healing wounds.
Differentiator
Problem solved
Functional benefit
Brands
- OCM™: Omeza Collagen Matrix - a first-of-its-kind drug-device combination wound matrix containing cold water fish peptides and other pharmaceutical-grade components designed to provide comprehensive therapy for all phases of wound healing.
Products and services
- OCM™ (Omeza Collagen Matrix) First-of-its-kind, FDA-cleared drug-device combination wound matrix made from cold water fish peptides and pharmaceutical-grade marine compounds. Delivered in single-use disposable vials (1-snap application, no refrigeration or mixing required), indicated for partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. Administered by healthcare professionals to support synthesis of new tissue across inflammation, proliferation, and remodeling phases.
- Omeza® Lidocaine Lavage Component of the Omeza products bundle designed to decrease inflammation, inhibit biofilm, and increase circulation at any site of care. Used in conjunction with Omeza Collagen Matrix and Omeza Skin Protectant as part of the episode-of-care model for chronic wound treatment.
- Omeza® Skin Protectant
Quantifiable outcome
- DFU clinical trial: 94% PAR at 12 weeks, 62% PAR at 4 weeks, 57% complete closure at 12 weeks (vs. 50% PAR / 17% closed for standard of care)
- +5 more outcomes
Companies that use Omeza
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
Omeza technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Omeza partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship / exclusive, core (government channel), core (clinical trial partner) and supporting (research collaboration).
- Advanced Solutionflagship / exclusiveExclusive national commercialization partnership covering all outpatient settings for OCM™ in the United States. Advanced Solution leverages its national distribution infrastructure, experienced sales force, and provider relationships across wound care providers, podiatrists, vascular surgeons, and hospital outpatient departments. Rollout began May 19, 2025 with full national availability by Summer 2025. Includes comprehensive sales training, provider education, sampling and launch strategy.
- Marathon Medicalcore (government channel)Prime vendor on the Veterans Affairs Federal Supply Schedule (FSS Contract Number 36F79718D0321). Provides OCM™ access to VA, DOD, and Indian Health Service physicians and clinics. Contact: 877-431-4753.
- Jobst Vascular Institute at ProMedica Health Systemcore (clinical trial partner)Conducted the Omeza-sponsored diabetic foot ulcer (DFU) clinical trial (n=19 OCM subjects) that demonstrated 94% PAR at 12 weeks vs. 50% for standard of care. Principal investigator Dr. Richard Simman, University of Toledo College of Medicine. Also conducted VLU clinical trial (n=33).
- University of Miamisupporting (research collaboration)Conducted in-vivo antimicrobial studies on OCM™ demonstrating significant antimicrobial decrease over controls in Pseudomonas aeruginosa and MRSA infected wounds. Results presented at SAWC 2024.
- University of Floridasupporting (research collaboration)Conducted the SAWC 2019 biofilm study on OCM™; poster presented and double-blind peer-reviewed at the Symposium on Advanced Wound Care.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
Omeza competitors and assessment
Company assessmentBroad incumbents
- ConvaTec Group: Global incumbent in advanced wound care (AQUACEL, Foam Lite, ConvaMax) and ostomy — overlapping HCP and outpatient channel relationships and broader portfolio contracts that compete with OCM™ for formulary space.
- Smith+Nephew: Global medical device incumbent with a large Advanced Wound Management portfolio (PICO NPWT, ALLEVYN, Duragen) and dedicated U.S. wound care sales force — the largest direct competitor for hospital and outpatient wound care contracts.
- Solventum (formerly 3M Health Care): Spun off 3M's Health Care business (including KCI V.A.C. negative pressure wound therapy, 3M Tegaderm, and Promogran Prisma) — directly competitive in advanced wound dressings and NPWT adjacent therapies.
- Integra LifeSciences: Specialty medical technology company offering regenerative wound matrices (Integra Dermal Regeneration Template, AmnioExcel, BioDFence) — directly comparable products and overlapping HCP customer base.
- Coloplast: Danish global leader in wound care (Biatain, Comfeel, Triad) and ostomy, with established U.S. advanced wound care sales force targeting the same podiatry, vascular, and outpatient wound care channels as OCM™.
Emerging players
- PolarityTE: Regenerative medicine company developing SkinTE and other autologous tissue technologies for chronic wounds and burns — emerging peer competing for advanced wound care accounts with novel regenerative approaches.
- Tissue Regenix (Acell): Regenerative medicine company developing dCELL decellularized tissue matrices for wound care — emerging peer in the regenerative wound matrix category targeting similar HCP customers with similar decellularized/marine-adjacent platforms.
- Bio-Tissue: Privately held regenerative medicine company marketing amniotic membrane-based wound care products (AmnioGraft, Prokera) — niche competitor in advanced wound care and ocular surface, smaller scale than Omeza but overlapping technology paradigm.
Direct peers
- Organogenesis Holdings: Public regenerative medicine company (ORGO) selling advanced wound care products including Dermagraft, Apligraf, and PuraPly, competing directly with OCM™ in diabetic foot ulcers and venous leg ulcers reimbursed under similar CMS codes.
- MiMedx Group: Public regenerative wound care and surgical recovery company (MDXG) using placental tissue allografts (EpiFix, AmnioFix) — directly competes with OCM™ in the advanced wound care and surgical recovery segments served by outpatient HCPs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Omeza social profiles
Digital presenceOmeza compliance and trust
Trust signalCompliance7 records
Omeza financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omeza leadership team
Management profileNumber of profiles
Profiles5 records
Omeza subsidiaries and ownership
Company hierarchySubsidiaries1 record
Omeza funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omeza M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omeza
What does Omeza do?
Omeza develops and manufactures OCM™ (Omeza Collagen Matrix), an FDA-cleared drug-device combination wound matrix made from cold water fish peptides and pharmaceutical-grade marine compounds. The product is delivered in single-use disposable vials and administered by healthcare professionals to address all phases of chronic wound healing — inflammation, proliferation, and remodeling — for partial/full-thickness wounds, diabetic foot ulcers, venous leg ulcers, pressure ulcers, tunneled wounds, surgical wounds, and trauma wounds. The portfolio also historically includes Omeza® Lidocaine Lavage and Omeza® Skin Protectant as part of a bundled treatment regimen, distributed nationally via an exclusive partnership with Advanced Solution and through the VA Federal Supply Schedule via Marathon Medical.
Is Omeza a public or private company?
Omeza is a private company. It is classified as venture growth investor backed and is currently operating.
When was Omeza founded?
Omeza was founded in 2014. It employs 11 to 50 people.
Where is Omeza based?
Omeza is headquartered in Sarasota, United States, in the North America region.
How does Omeza make money?
Three revenue lines are on record. OCM™ product sales via exclusive distributor is the primary driver. The others are government channel sales (VA/DOD/IHS) and direct commercial product sales.
Who are Omeza's main competitors?
Broad incumbents on record are ConvaTec Group, Smith+Nephew, Solventum (formerly 3M Health Care), Integra LifeSciences and Coloplast. Emerging players are PolarityTE, Tissue Regenix (Acell) and Bio-Tissue. Direct peers are Organogenesis Holdings and MiMedx Group.
Does Omeza have an API?
No public API is recorded for Omeza.
What industry is Omeza in?
Omeza's product category is Advanced Wound Care. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAHALAD, Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips). Its NAICS code is 339113 and its SIC code is 3841.